Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Treatment Promising For Ulcerative Colitis Sufferers

04.01.2006


For people with the chronic disease ulcerative colitis, life can be limited to few social functions and trips away from home.

A promising new therapy pioneered by University of Kentucky gastroenterology specialists may offer improved lives to patients suffering from moderate to severe forms of the disease.

Ulcerative colitis causes inflammation and ulcers in the colon, leading to abdominal pain and such frequent trips to the bathroom that normal routines can be disrupted. Finding the right treatment can be difficult, with therapies that may include steroids and anti-inflammatory drugs, or possibly surgery in as many as 25 to 40 percent of ulcerative colitis patients.



A drug already used for other inflammatory diseases, including Crohn’s and rheumatoid arthritis, has received FDA approval for treatment of ulcerative colitis after performing well in clinical trials. UK was a primary investigator of infliximab, brand name Remicade®, and enrolled the largest study group in North America.

"It’s a very welcome addition to our treatment options," said Willem J.S. deVilliers, M.D., Ph.D., chief of the UK Division of Digestive Diseases and Nutrition. DeVilliers co-authored a report of the trial, which was recently published in the New England Journal of Medicine.

One of the study participants is Robert Lewandowski, of Hager Hill in Johnson County. Lewandowski was diagnosed with the disease a decade ago and saw the retirement plans he and his wife made slipping away as he became more and more reluctant to leave home.

"The first thing you do is when you think about going somewhere, you have to think about where the bathroom is and how quickly you can get to it," Lewandowski said. "Eventually, you stop going and doing things because it’s too much of a problem."

Lewandowski’s disease went into remission after a few years, then reappeared, sending him to the bathroom 20 or more times a day. Therapies he used in the past didn’t work, so his physician referred him to the clinical study at UK. He saw an improvement almost immediately, and a year later, he is able to lead a normal life, with no symptoms of the disease. "I’m happy," he said.

The medication is administered intravenously, with an initial regimen of three doses of infliximab, followed by maintenance infusions every eight weeks. Nearly 70 percent of patients receiving the drug experienced clinical response and remission early in the trial, and nearly all had significant results after one year of therapy.

For more information, contact the UK Division of Digestive Diseases and Nutrition at (859) 323-5575.

Beth Goins | EurekAlert!
Further information:
http://www.uky.edu

More articles from Health and Medicine:

nachricht Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine

nachricht 'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

MEMS chips get metatlenses

21.02.2018 | Physics and Astronomy

International team publishes roadmap to enhance radioresistance for space colonization

21.02.2018 | Physics and Astronomy

World's first solar fuels reactor for night passes test

21.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>